Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 2/20 | 0.33 |
| ▸ | TDP2 | O95551 | 2/20 | 0.33 |
| ▸ | NSD2 | O96028 | 2/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GALK1 | P51570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL7616616 | 0.98 | DNMT1 (0.38) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL5800741 | 0.93 | DNMT1 (0.41) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL610295 | 0.91 | DNMT1 (0.42) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL11791565 | 0.90 | DNMT1 (0.39) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL2160619 | 0.89 | DNMT1 (0.41) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL10379983 | 0.89 | DNMT1 (0.41) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL11416072 | 0.88 | DNMT1 (0.40) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL600168 | 0.88 | DNMT1 (0.40) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL6830995 | 0.86 | DNMT1 (0.39) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL8741891 | 0.86 | DNMT1 (0.39) | DNMT1TP53MAPTSTAT3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2868654-B1 | Method for making a tris-(2 hydroxyethyl)-methylammonium methylsulfate fatty acid ester | EVONIK DEGUSSA GMBH (DE) | 2018-09-19 | — | — | EP | claimed |
| US-4608407-A | AMINE SALTS OF PHOSPHORUS-CONTAINING COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-08-26 | — | — | US | claimed |
| US-10583078-B2 | Product and method for the temporary shaping of keratin-containing fibers | HENKEL AG & CO. KGAA (DE) | 2020-03-10 | — | — | US | disclosed |
| EP-3463474-A1 | METHODS FOR TREATING SMARCB1 DEFICIENT CANCER OR PAZOPANIB RESISTANT CANCER | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2019-04-10 | — | — | EP | disclosed |
| US-RE47300-E1 | Mitochondrially delivered anti-cancer compounds | CANCURE LIMITED (AU) | 2019-03-19 | — | — | US | disclosed |
| US-20190008856-A1 | INHIBITORS OF ATAXIA-TELANGIECTASIA MUTATED AND RAD3-RELATED PROTEIN KINASE (ATR) FOR USE IN METHODS OF TREATING CANCER | BREAST CANCER NOW (GB) | 2019-01-10 | — | — | US | disclosed |
| WO-2018224536-A1 | PARP INHIBITORS FOR USE IN TREATING CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2018-12-13 | — | — | WO | disclosed |
| US-20180112258-A1 | MEDICAL USES AND METHODS FOR TREATING CANCER USING MONOPOLAR SPINDLE 1 (MPS1) KINASE INHIBITORS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2018-04-26 | — | — | US | disclosed |
| EP-2718436-B1 | MATERIALS AND METHODS FOR TREATING PTEN MUTATED OR DEFICIENT CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2018-03-28 | — | — | EP | disclosed |
| EP-3283075-A1 | MEDICAL USES AND METHODS FOR TREATING CANCER USING MONOPOLAR SPINDLE 1 (MPS1) KINASE INHIBITORS | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2018-02-21 | — | — | EP | disclosed |
| US-20180042834-A1 | PRODUCT AND METHOD FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS | HENKEL AG & CO. KGAA (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20010051606-A1 | Compounds and their uses | RADEMACHER GROUP LIMITED (GB) | 2001-12-13 | — | — | US | disclosed |
| WO-2001085746-A1 | INOSITOL PHOSPHOGLYCAN DERIVATIVES AND THEIR MEDICAL USES | RODARIS PHARMACEUTICALS LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085747-A1 | ALKYLATED INOSITOLGLYCANS AND THEIR USE | RODARIS PHARMACEUTICALS LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| US-20010041677-A1 | Compounds and their uses | RODARIS PHARMACEUTICALS LIMITED (GB) | 2001-11-15 | — | — | US | disclosed |
| WO-2001085740-A2 | INOSITOLGLYCANS AND THEIR USES | RODARIS PHARMACEUTICALS LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085745-A1 | INOSITOL PHOSPHOGLYCAN DERIVATIVES AND THEIR MEDICAL USES | RODARIS PHARMACEUTICALS LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| US-5981492-A | ADMINISTERED TO THE PATIENT TO INHIBIT THROMBOCYTE AGGREGATION, THE METASTASIZATION OF CARCINOMA CELLS, THE BINDING OF OSTEOCLASTS TO THE BONE SURFACE, OR FOR THE TREATMENT OF THROMBOSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| US-5458127-A | Includes a chelated paramagnetic ion | IMARX PHARMACEUTICAL CORP. (US) | 1995-10-17 | — | — | US | disclosed |
| EP-0055847-B1 | PRESSURE SENSITIVE RECORDING UNIT | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1986-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042834-A1 | PRODUCT AND METHOD FOR THE TEMPORARY SHAPING OF KERATIN-CONTAINING FIBERS | KRT18, DSG1, CUTA | DNMT1 39/4885TP53 58/4885MAPT 1438/4885 |
| US-20190008856-A1 | INHIBITORS OF ATAXIA-TELANGIECTASIA MUTATED AND RAD3-RELATED PROTEIN KINASE (ATR) FOR USE IN METHODS OF TREATING CANCER | ATR, RAD50, ATM | DNMT1 2112/4885TP53 52/4885MAPT 3995/4885 |
| US-10583078-B2 | Product and method for the temporary shaping of keratin-containing fibers | KRT18, DSG1, CUTA | DNMT1 39/4885TP53 58/4885MAPT 1438/4885 |
| US-20180112258-A1 | MEDICAL USES AND METHODS FOR TREATING CANCER USING MONOPOLAR SPINDLE 1 (MPS1) KINASE INHIBITORS | BUB1B, BUB1, AURKC | DNMT1 2999/4885TP53 754/4885MAPT 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.